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Abstract
Background: Ezetimibe (Zetia®) is a potent inhibitor of cholesterol absorption that has been
approved for the treatment of hypercholesterolemia. Statin, an inhibitor of cholesterol synthesis,
is the first-choice drug to reduce low-density lipoprotein-cholesterol (LDL-C) for patients with
hypercholesterolemia, due to its strong effect to lower the circulating LDL-C levels. Because a high
dose of statins cause concern about rhabdomyolysis, it is sometimes difficult to achieve the
guideline-recommended levels of LDL-C in high-risk patients with hypercholesterolemia treated
with statin monotherapy. Ezetimibe has been reported to reduce LDL-C safely with both
monotherapy and combination therapy with statins.
Results:  To investigate the effect of ezetimibe as "add-on" therapy to statin on
hypercholesterolemia, we examined biomarkers and vascular endothelial function in 14 patients
with hypercholesterolemia before and after the 22-week ezetimibe add-on therapy. Ezetimibe add-
on therapy reduced LDL-C by 24% compared with baseline (p < 0.005), with 13 patients (93%)
reaching their LDL cholesterol goals. Of the Ezetimibe add-on therapy significantly improved not
only LDL-C, high-density lipoprotein-cholesterol (HDL-C), and apolipoprotein (apo)B levels, but
also reduced levels of triglyceride (TG), the ratio of LDL/HDL-C, the ratio of apoB/apoA-I, and a
biomarker for oxidative stress (d-ROMs). Furthermore, ezetimibe add-on therapy improved
vascular endothelial function in high-risk patients with hypercholesterolemia.
Conclusion: In conclusion, ezetimibe as add-on therapy to statin might be a therapeutic good
option for high-risk patients with atherosclerosis.
Background
Atherosclerosis is the most common pathological process
that leads to cardiovascular diseases, a disease of large-
and medium-sized arteries that is characterized by forma-
tion of atherosclerotic plaques consisting of necrotic
cores, calcified regions, accumulated modified lipids,
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inflamed endothelial cells, smooth muscle cells, leuko-
cytes, and foam cells [1]. Although low-density lipopro-
tein (LDL) remains the most important and powerful risk
factor for atherosclerosis, vascular inflammation- and oxi-
dative stress-induced mechanisms of atherosclerosis have
gained tremendous interest in the past 20 years [1-4]. LDL
are susceptible to structural modifications by oxidation,
particularly the small dense LDL particles. Under proath-
erogenic conditions, nitric oxide production from
endothelial cells is reduced and the burden of reactive
oxygen species (ROS) is increased [5,6].
Ezetimibe (Zetia®) is an epoch-making cholesterol trans-
porter inhibitor in the small intestine to treat dyslipi-
demia patients with high levels of LDL-C [7]. The
mechanism is absorption of both food-derived choles-
terol (~25%) and bile acid-derived reabsorbed cholesterol
(~75%). Generally, it is difficult to achieve the target LDL-
C levels by dietary therapy alone in patients with high
LDL-C. HMG-CoA (or 3-hydroxy-3-methyl-glutaryl coen-
zyme A) reductase inhibitor, statin, is the first choice drug
to reduce LDL-C for patients with high LDL-C, in that its
strong effect to be lowered the circulating LDL-C levels.
Because a high dose of statins cause concern about rhab-
domyolysis, it is sometimes difficult to achieve the guide-
line-recommended levels of LDL-C in patients with high
LDL-C treated with statin monotherapy. Ezetimibe has
been reported to reduce LDL-C safely with both mono-
therapy and combination therapy with statins [8-10].
Ezetimibe is especially expected to be effective in statin-
intolerant patients with high LDL-C [11]. However, it is
still unclear whether or not the LDL-C-lowering by
ezetimibe is effective to suppress cardiovascular events or
death [12].
In the present prospective study, we investigated the con-
tribution of ezetimibe add-on therapy to the control of
hypercholesterolemia in high-risk patients on statin mon-
otherapy, especially focused on lipid profiles and
endothelial function.
Results
To investigate the effect of ezetimibe as "add-on" therapy
to statin on hypercholesterolemia, we examined biomar-
kers and vascular endothelial function in 14 high-risk
patients for cardiovascular disease with hypercholestero-
lemia (Table 1). The add-on therapy of ezetimibe to statin
monotherapy was safe and effective for the management
of dyslipidemia in high-risk patients. After 22 weeks,
ezetimibe add-on therapy reduced LDL-C by 24% com-
pared with baseline (p < 0.005), with 13 patients (93%)
reaching their LDL cholesterol goals. Of the Ezetimibe
add-on therapy significantly improved not only LDL-C,
high-density lipoprotein-cholesterol (HDL-C), and apoli-
poprotein (apo)B levels, but also reduced levels of triglyc-
eride (TG) and d-ROMs (Table 2).
Effects of ezetimibe on the ratio of LDL/HDL cholesterol in 
patients with hypercholesterolemia
To determine atheroprotective effects of ezetimibe, we
evaluated ratios of proatherogemic to antiatherogenic
lipoprotein measurements, LDL-C to HDL-C ratio (LDL/
HDL-C) and apoB to apoA-I ratio (apoB/A-I). As shown in
Figures 1 and 2, ezetimibe improved the ratio of LDL/
HDL-C and apoB/A-I. The most impressive data is that
ezetimibe improved the ratio of LDL/HDL-C (by 28%;
from 2.6 to 1.9; p = 0.0037) as shown in Figure 1. Further-
more, ezetimibe add-on therapy significantly reduced the
ratio of apoB/A-I in high-risk patients with hypercholeste-
rolemia (by 22%; from 0.8 to 0.6; p = 0.0052) as shown
in Figure 2,.
Effects of ezetimibe on a biomarker for oxidative stress in 
patients with hypercholesterolemia
A large numbers of literature has linked oxidative stress
with hypertension and atherosclerosis [13]. To examine
Table 1: Baseline characteristics of the patients included the study
Characteristic Value
Age (year) 62 ± 10
Sex Female 5 (36%)
Levels of vascular risk Coronary artery disease 11 (79%)
Diabetes mellitus 6 (43%)
Peripheral artery disease 1 (7%)
Stroke 3 (21%)
Hypertension 10 (71%)
Statins Strong statin 9 (64%)
Co-medication Renin-angiotensin system inhibitors 14 (100%)
β-blockers 11 (79%)
Aspirin 10 (71%)
Antidiabetic agents 4 (31%)
Data were shown as mean ± SD or as percentages of the total number of patients.Lipids in Health and Disease 2009, 8:41 http://www.lipidworld.com/content/8/1/41
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whether ezetimibe improves oxidative stress or not, we
measured the derivatives of reactive oxidative metabolites
(d-ROMs) test as an oxidative biomarker in patients with
hypercholesterolemia before and after the ezetimibe add-
on therapy with a statin (Table 2). As shown in Figure 3,
the ezetimibe add-on therapy remarkably reduced d-
ROMs levels in high-risk patients with hypercholestero-
lemia (11% reduction, p = 0.014).
Effects of ezetimibe on vascular endothelial function in 
patients with hypercholesterolemia
Vascular endothelial dysfunction has been considered as
the first step of atherosclerosis, we examined endothelial
function using a fingertip peripheral arterial tonometry
device system, EndoPAT™ (Itamar Medical Ltd., Caesarea,
Israel), as a surrogate marker for cardiovascular events.
After 22 weeks of ezetimibe add-on combination therapy
Table 2: Lipid and other biomarkers at baseline and after the ezetimibe add-on therapy
Biomarkers Baseline At 22 weeks of Ezetimibe add-on therapy p-value
Triglyceride (mg/dL) 187 ± 109 134 ± 66 (-28%) 0.010
LDL-cholesterol (mg/dL) 134 ± 20 102 ± 13 (-24%) 0.020
HDL-cholesterol (mg/dL) 52 ± 11 56 ± 10 0.612
Free fatty acid (μEq/L) 377 ± 232 379 ± 204 0.726
RLP-cholesterol (mg/dL) 9.9 ± 7.0 8.8 ± 5.3 0.188
Apolipoprotein B (mg/dL) 107 ± 17 87 ± 12 (-18%) 0.004
Apolipoprotein A-I (mg/dL) 134 ± 22 141 ± 23 0.121
MDA-LDL (mg/dL) 113 ± 28 100 ± 28 (-12%) 0.039
Glucose (mg/dL) 118 ± 24 110 ± 16 0.152
HbA1c (%) 5.9 ± 0.7 6.0 ± 0.8 0.531
hs-CRP (mg/dL) 0.11 ± 0.09 0.13 ± 0.18 0.872
dROMs (U Carr) 368 ± 47 329 ± 45 (-11%) 0.014
Data are expressed as mean ± SD or as number (%). The Student's paired t-test was used for pairwise comparisons between values before and after 
administration of ezetimibe for 22 weeeks (n = 14). RLP, remnant lipoprotein; MDA, malondialdehyde-modified; hs-CRP, high-sensitivity C reactive 
protein; dROMs, derivatives of the reactive oxidative metabolites.
Ezetimibe improved LDL/HDL-cholesterol ratio in patients  with hypercholesterolemia Figure 1
Ezetimibe improved LDL/HDL-cholesterol ratio in 
patients with hypercholesterolemia. Ezetimibe 
improved LDL/HDL-cholesterol ratio in patients with hyper-
cholesterolemia. LDL- and HDL-cholesterol were measured 
before and after 22-week ezetimibe administration in 
patients with atherosclerosis-prone hypercholesterolemia (n 
= 14). Bars represent the mean value of the ratio ± SD.
Ezetimibe improved apolipoprotein B (apoB) to apolipopro- tein A-I (apoA-I) ratio in patients with hypercholesterolemia Figure 2
Ezetimibe improved apolipoprotein B (apoB) to 
apolipoprotein A-I (apoA-I) ratio in patients with 
hypercholesterolemia. Ezetimibe improved apoB to 
apoA-I ratio in patients with hypercholesterolemia. apoB and 
apoA were measured before and after 22-week ezetimibe 
administration in patients with atherosclerosis-prone hyperc-
holesterolemia (n = 14). Bars represent the mean value of 
the ratio ± SD.Lipids in Health and Disease 2009, 8:41 http://www.lipidworld.com/content/8/1/41
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with a statin, reactive hyperemia index (RHI) measured by
the EndoPAT™ was improved in high-risk patients with
hypercholesterolemia (Figure 4). Overall, there was a 14%
increase in RHI at the 22nd week (from 1.31 to 1.53; p =
0.020). According to a literature [14], an RHI < 1.35 was
found to have a sensitivity of 80% and a specificity of 85%
to identify patients with coronary endothelial dysfunc-
tion.
Discussion
Our results suggest that the add-on therapy of ezetimibe
to statin monotherapy is safe and effective for the manage-
ment of dyslipidemia in high-risk patients. In the present
study, we clearly showed that ezetimibe add-on therapy
reduced levels of LDL-C and apoB as well as TG and d-
ROMs.
Ezetimibe, a novel lipid-lowering agent, selectively inhib-
its intestinal cholesterol absorption, reducing total choles-
terol and TG levels and also reducing the development of
atherosclerosis in apoE knockout mice [15,16]. A sterol
transporter, Niemann-Pick C1-Like 1 (NPC1L1) is
involved in subcellular cholesterol trafficking and plays a
critical role in the absorption of intestinal cholesterol
[17,18]. NPC1L1-deficient mice exhibit a substantial
reduction in absorbed cholesterol, on which ezetimibe
had no effect [18]. Thereafter, the molecular target of
ezetimibe was revealed to be NPC1L1, which is a critical
mediator of cholesterol absorption and an essential com-
ponent of ezetimibe-sensitive pathway [16].
The most impressive data is that ezetimibe improved the
ratio of LDL/HDL-C (p < 0.005) as shown in Figure 1.
According to a recent literature, the lipid ratio of LDL/
HDL-C is better monitoring predictors than single stand-
ard lipids including total cholesterol, LDL-C, and HDL-C
[19]. As for initial risk measurements, several previous
cohort studies and a meta-analysis study suggest that the
ratio of LDL/HDL-C also have greater independent predic-
tive values for coronary heart disease than individual
serum total cholesterol or LDL-cholesterol levels [20-24].
In the current therapy for hypercholesterolemia,
ezetimibe may be the most powerful agent to improve the
LDL/HDL ratio compared to any statin monotherapy. Fur-
thermore, ezetimibe add-on therapy significantly reduced
the ratio of apoB to apoA-I in high-risk patients with
hypercholesterolemia (p < 0.01, Figure 2). Patients who
were treated adequately according to current guidelines
(i.e., LDL cholesterol ≤ 100 mg/dL) still had residual
major cardiovascular event risks that could be recognized
by the evaluation of levels of non-HDL cholesterol or
apoB [22]. On-treatment levels of non-HDL cholesterol
and apoB are considered to be more closely associated
with cardiovascular outcome than levels of LDL choles-
terol [25]. These data suggest that ezetimibe not only
Ezetimibe reduced a circulating oxidative marker, derivatives  of reactive oxidative metabolites (d-ROMs), in patients with  atherosclerosis-prone with hypercholesterolemia Figure 3
Ezetimibe reduced a circulating oxidative marker, 
derivatives of reactive oxidative metabolites (d-
ROMs), in patients with atherosclerosis-prone with 
hypercholesterolemia. Measurements of d-ROMs were 
assessed before and after 22-week ezetimibe administration 
in patients with atherosclerosis-prone hypercholesterolemia 
(n = 14). Bars represent the mean value of the ratio ± SD.
Ezetimibe improved reactive hyperemia index (RHI) by  EndoPAT™ in patients with hypercholesterolemia Figure 4
Ezetimibe improved reactive hyperemia index (RHI) 
by EndoPAT™ in patients with hypercholestero-
lemia. RHI were measured before and after 22-week 
ezetimibe administration in patients with hypercholestero-
lemia (n = 14). According to Bonetti P.O., et al, [14], an RHI 
< 1.35 was found to have a sensitivity of 80% and a specificity 
of 85% to identify patients with coronary endothelial dysfunc-
tion. Bars represent the mean value of the ratio ± SD.
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reduced serum levels of LDL cholesterol but also improve
total lipid profiles.
A large number of reports in the literature has linked oxi-
dative stress with hypertension and atherosclerosis [13].
The ezetimibe add-on therapy remarkably reduced an oxi-
dative stress marker in high-risk patients with hypercho-
lesterolemia (Figure 3). Considering that ezetimibe
monotherapy or a combination therapy with simvastatin
decreased LDL tendency to peroxidation, ezetimibe may
have favorable pleiotropic effects beyond the LDL-choles-
terol lowering [26,27]. These data suggest that ezetimibe
could contribute to atheroprotective properties through
effective antioxidant actions. Since oxidized LDL induces
expression of a nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidase, gp91phox, and ROS generation
in vascular endothelial cells [28], ezetimibe may attenuate
ROS production through reduction of circulating ox-LDL
in patients with hypercholesterolemia.
Endothelial dysfunction is the initial step of atherosclero-
sis. A recent report demonstrated that ezetimibe treatment
attenuated vascular functions, such as endothelial dys-
function, oxidative stress, and inflammation in high-fat
fed apoE-deficient mice [29]. Ezetimibe treatment mark-
edly inhibited the development of lipid-rich plaque and
also significantly improved endothelial dysfunction
assessed by the vasodilator response to acetylcholine [30],
accompanied by inhibition of interleukin-6 mRNA and
an increase in endothelial nitric oxide synthase mRNA in
the aorta. Furthermore, ezetimibe suppressed ROS gener-
ation and the ubiquitination-proteasome system in the
aorta. In the present study, ezetimibe add-on therapy
achieved effective RHI-improvement in high-risk patients
with hypercholesterolemia (p < 0.05, Figure 4). To our
knowledge, this is the first clinical data about ezetimibe-
improving vascular endothelial function detected by
EndoPAT.
NPC1L1 is widely expressed in many human tissues, with
the highest expression in the small intestine as well as in
the liver [31,32]. Therefore, ezetimibe inhibits cholesterol
absorption in the small intestine, reduces enterohepatic
circulation of cholesterol, reduces uptake of free choles-
terol in hepatocytes, and should affect metabolic path-
ways in the liver [33]. Ezetimibe improved hepatic insulin
signaling as well as hepatic steatosis in Zucker Obese fatty
(ZOF) rats. Ezetimibe also restored insulin sensitivity in
steatotic hepatocytes in vitro by a reduction in hepatic ROS
generation, Janus-family tyrosine kinase (JNK) activation,
and endoplasmic reticulum stress. In addition, ezetimibe
recovered insulin-induced Akt activation, and reduced
gluconeogenic genesin the liver of ZOF rats and cultured
steatotic hepatocytes [33]. Other studies have shown that
ROS-dependent activation of JNK plays a role in the devel-
oping insulin resistance [34-36]. In recent clinical studies,
ezetimibe treatment has been considered as an effective
therapeutic option for non-alcoholic fatty liver disease
(NAFLD) [31,37,38]. Several reports have concluded that
ezetimibe monotherapy not only protects against high fat
diet-induced dyslipidemia but also attenuates liver steato-
sis in an experimental NAFLD model [39,40]. In apoE
knockout mice, liver weight was significantly decreased
and lipid accumulation in the liver was also dramatically
inhibited in the ezetimibe-treated group [29]. These accu-
mulating data suggest that the inhibition of NPC1L1-
dependent cholesterol uptake by ezetimibe may be a suit-
able therapeutic target for treatment of not only hypercho-
lesterolemia but also broader aspects of metabolic
disorders in patients with type 2 diabetes and/or meta-
bolic syndrome (Figure 5).
Conclusion
Our results suggest that ezetimibe improves lipid profiles,
reduces oxidative stress, and improve endothelial func-
tion in high-risk patients with dyslipidemia, which may
contribute to prevention atherosclerosis in vasculature. As
an atheroprotective drug, ezetimibe may be a suitable
therapeutic target for treatment of not only hypercholeste-
rolemia but also broader aspects of metabolic disorders in
patients with type 2 diabetes or metabolic syndrome or
both.
Methods
Subjects
The study included 14 Japanese high-risk patients (36%
female) with coronary artery disease or equivalents
treated with statin monotherapy in the Department of
Cardioangiology, Kitasato University Hospital. No
patients achieved the guideline-recommended levels of
LDL-C [41,42], concretely, LDL-C < 100 mg/dL for coro-
nary artery disease patients and < 120 mg/dL for high-risk
patients with diabetes, cerebrovascular disease, and/or
peripheral arterial occlusive disease. Ezetimibe from Bayer
Co., Ltd. (Osaka, Japan) and Schering-Plough K.K.
(Tokyo, Japan) was administered once a day (10 mg/day)
to all patients for 22 weeks. Lipid profiles, biochemical
parameters, and adverse effects were monitored every 4-8
week through the study. None of the patients took any
other drugs and/or any advice for diet and lifestyle modi-
fication that affect lipid profile or lipid metabolism.
Except the ezetimibe add-on therapy, every medication
was continued without any dose changes during the study
period. Total calorie intake and composition of the diet
were kept constant for each patient.
All subjects gave written informed consent before partici-
pating in this study, and the ethics committee of the Kita-
sato University Hospital approved the study design.Lipids in Health and Disease 2009, 8:41 http://www.lipidworld.com/content/8/1/41
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Measurement of serum sample
Fasting blood samples were taken from each of the 14
enrolled patients before and after the ezetimibe add-on
study. Serum was centrifuged (1500 g for 15 min at 4°C)
and stored at 4°C until measurement within couple days
for biochemical markers, such as TG, LDL-C, HDL-C,
alanine aminotransferase, aspartate aminotransferase,
serum creatinine, creatine kinase, free fatty acid, remnant
lipoprotein-cholesterol, apoB, apoA-I, malondialdehyde-
modified-LDL, glucose, HbA1c, and high-sensitivity C
reactive protein.
Measurement of d-ROMs
Serum was centrifuged (1500 g for 15 min at 4°C) and
stored at -20°C until measurement within one week for
free oxygen radical monitor, d-ROMs. The d-ROMs were
evaluated spectrophotometrically by Free Radical Analyti-
cal System (FRAS4®, Diacron International, Grosseto,
Italy) [43,44]. The d-ROMs test is based on the ability of
transition metals to catalyze, in the presence of peroxides,
the formation of free radicals which are then trapped by
an alchylamine. The alchylamine reacts forming a colored
radical detectable at 505 nm through a kinetic reaction
which is linear up to 500 U Carr (Carratelli units). The
determination of free radicals can be made with a normal
spectrophotometer. The normal range has been deter-
mined as 250-300 U Carr [43].
Measurement of vascular endothelial function by 
EndoPAT
Vascular endothelial function was examined reactive
hyperemia by EndoPAT™ [45] in patients with hypercho-
lesterolemia. Using a fingertip peripheral arterial tonome-
try device, we measured digital pulse amplitude in
Schematic diagram of the proposed mechanisms of ezetimibe-induced atheroprotective effects Figure 5
Schematic diagram of the proposed mechanisms of ezetimibe-induced atheroprotective effects. LDL-C, low-
density lipoprotein-cholesterol; ox-LDL, oxidized LDL; VEGF, vascular endothelial growth factor; LPS, lipopolysaccharide; 
MCP-1, monocyte chemotactic protein-1; CM, chylomicrons; TG, triglyceride; HDL-C, high-density lipoprotein-cholesterol; 
NAFLD, non-alcoholic fatty liver disease; NPC1L1, Nieman-Pick C1-like 1; apoB, apolipoprotein B; VLDL, very-low density 
lipoprotein; JNK, Janus-family tyrosine kinase.
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patients with hypercholesterolemia for 5 minutes at base-
line and after a reactive hyperemia induced by a 5-minute
forearm cuff occlusion. RHI was measured before and
after 22-week ezetimibe administration in patients with
hypercholesterolemia.
Statistical analysis
The results were expressed as mean ± SD. The Student's
paired t-test was used for patients between values before
and after ezetimibe administration. A value of p < 0.05
was considered to be statistically significant.
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